AETC National Coordinating Resource Center

François-Xavier Bagnoud Center
School of Nursing, Rutgers, The State University of New Jersey
65 Bergen Street, 8th floor
Newark, NJ 07101

phone: (973) 972-5141
fax: (973) 972-0397
email: [email protected]

The AETC National Coordinating Resource Center provides education, training, and capacity building resources for the AETC Program to support the mission to offer timely, high quality, state-of-the-science information to healthcare professionals working with existing and emerging populations affected by HIV.

Resources: 50

Title Publication Datesort ascending Review Date
Assisting HIV Patients Returning to Mexico and Central America / Asistiendo a los Pacientes que Regresan a México y Centroamérica 9/20/2018
Flyer: Hepatitis C Screening and Treatment in People Living with HIV/AIDS 6/29/2018
Brand and Generic Names of ARVs in the United States and Mexico 6/20/2018
Hep C Free Postcard 5/31/2018
Passport to Cure 3/9/2018 5/31/2018
Non-Occupational Post-Exposure Prophylaxis (nPEP) Toolkit 1/26/2018 9/7/2018
Prescribing nPEP Infographic 1/22/2018
AETC National HIV Curriculum 10/20/2017
AETC Program Infographic 9/14/2017 8/17/2018
Ryan White Clinical Care Conference 8/23/2017
HIV/HCV Co-infection: An AETC National Curriculum 7/13/2017
Barriers to Curing Hepatitis C Virus among Coinfected People Living with HIV Infographic 3/22/2017
The Effects of Stigma on People Living with HIV in Rural America 8/25/2016
AETC Program HIV IPE Projects Infographic 7/28/2016
Website Accessibility Infographic 6/1/2016
E-Learn Committee Webinar: #AETCApproved: Leveraging National, Regional & Local AETC Social Media Efforts 5/19/2016
Guidelines for Prevention and Treatment of Opportunistic Infections in HIV-Infected Adults and Adolescents: Comprehensive Slide Sets 5/10/2016
Advanced Practice Nursing Education in HIV Care Infographic 11/11/2015
E-Learn Committee Webinar: Caption This! Update on Section 508 Compliance and Captioning Options 9/30/2015
Preconception Care & the Elimination of Perinatal Transmission Infographic 9/4/2015
Patient Self-Management Infographic 7/1/2015
Rural vs. Non-Rural HIV Care Continuum Differences: Study Results and AETC Program Interventions 6/17/2015
Treating People Living with HIV in Rural U.S. Territories Infographic 5/19/2015
HIV Among People Aged 50 and Older: Trainer Slides 5/19/2015
HIV and Aging Toolkit 4/29/2015
Pharmacy Recommendations for HIV and Aging 4/1/2015
HIV and Aging Infographic 4/1/2015
Addressing the Needs of Black Women in HIV Prevention in the U.S. Infographic 2/23/2015
Barriers to Viral Load Suppression Infographic 1/28/2015
HIV & Social Determinants of Black MSM in the U.S. 12/22/2014
Health Disparities Collaborative Webinar: What to do with Social Determinants of HIV? 12/10/2014
Routine HIV Testing Rates in U.S. Healthcare Facilities Infographic 11/24/2014
HIV and Mood Disorders Infographic 10/24/2014
Integrating Video into Medical Education and Training Infographic 9/25/2014
Health Disparities Collaborative Webinar: HIV Testing and Treatment in Arizona's American Indian Communities 9/10/2014
Resources for HRSA HAB Performance Measures 7/31/2014 2/12/2018
Resources for Accessibility 7/30/2014 7/20/2018
AETC Health Care Disparities Collaborative Webinar: UCLA PAETC MAI Workforce Development Project: Developing the Next Generation of Spanish-Speaking HIV Providers 5/23/2014
E-learn Collaborative Webinar: Using Google Analytics 5/13/2014
AETC NCRC YouTube Submission Guidelines 2/28/2014 7/13/2015
Outreach Worker Program Tools 2/19/2014
Patient Navigator Program Tools 2/19/2014
Technology-Based Interventions Tools 2/19/2014
Resources for Engagement in Care Capacity Building 2/19/2014
Traditional Case Management Tools 2/13/2014
ARTAS Linkage Case Management Tools 2/13/2014
Clinic-Wide Messaging Tools 2/8/2014
A Low-Effort, Clinic-Wide Intervention Improves Attendance for HIV Primary Care: Publication and Corresponding Tools 2/6/2014 4/19/2018
What to Consider when Consulting with Latino Patients 12/16/2013
E-learn Collaborative Webinar: Tips for Creating Professional Resources 11/12/2013

Articles: 38

  • Rapid ART Start

    Susa Coffey's picture

    The International AIDS Society (IAS)-USA recently released its 2018 HIV treatment and prevention recommendations. The document is particularly notable for its discussion of "When to Start ART."

    The IAS-USA recommends "rapid" or immediate start of ART...

  • Doravirine--New NNRTI Approved by FDA

    Susa Coffey's picture

    The U.S. Food and Drug Administration has approved the NNRTI doravirine for use in initial HIV therapy. FDA approval was based on 48-week results of 2 Phase III studies in treatment-naive persons that showed doravirine + 2 NRTIs resulted in similar rates of viral suppression at 48...

  • Dolutegravir in Early Pregnancy: Updates on Possible Risk of Neural Tube Defects

    Jennifer Cocohoba's picture

    Integrase inhibitors have become primary treatment for most people living with HIV; however, the impact of newer integrase inhibitors on pregnancy outcomes has not been well described. Researchers for the observational Tsepamo study have been examining birth outcomes in Botswanan...

  • Updates in Antiretroviral Treatment during Pregnancy: Dolutegravir in Late Pregnancy

    Jennifer Cocohoba's picture

    Although DTG currently is not a desirable medication for women to take pre-conception (see Dolutegravir in Early Pregnancy: Updates on Possible Risk of Neural Tube Defects), findings from the DolPHIN study suggest that it may be a very useful agent for women who start ART during...

  • Tenofovir Alafenamide (TAF) and Darunavir/Cobicistat in Pregnant Women

    Jennifer Cocohoba's picture

    Two pharmacokinetic studies from AIDS 2018 help elucidate the disposition of tenofovir alafenamide (TAF) and cobicistat-boosted darunavir during pregnancy.

    The IMPAACT P1026s study examined plasma concentrations of TAF with and without cobicistat in 43...

  • TargetHIV: New Name, New Look

    Nicolé H. Mandel's picture

    It's easier than ever to stay on target. The Health Resources and Services Administration's (HRSA) Ryan White HIV/AIDS Program (RWHAP) technical assistance (TA) and training website has undergone a major update to make it easier for users to access tools and materials for the RWHAP. The website...

  • U=U in PARTNER2 Study of MSM

    Susa Coffey's picture

    PARTNER1, whose results were reported last year,(1) was one of the studies that supported current efforts to promote the growing scientific consensus supporting "Treatment as Prevention" (TasP) or Undetectable = Untransmittable (U=U).

    PARTNER1 evaluated HIV...

  • Dolutegravir + 3TC in Initial Therapy

    Susa Coffey's picture

    As we have commented in the past, initial ARV regimens consisting of 2 drugs tend to perform poorly in comparison with currently recommended 3-drug regimens. Yet, given toxicity concerns about some ARVs (particularly about tenofovir DF and abacavir) and cost concerns about 3-drug regimens, the...

  • Darunavir/Cobicistat/FTC/TAF Coformulation Approved; More Data from EMERALD Switch Study

    Susa Coffey's picture

    The U.S. Food and Drug Administration has given approval to a coformulation of darunavir 800 mg/cobicistat 150 mg/emtricitabine 200 mg/tenofovir alafenamide (TAF) 10 mg, to be marketed under the brand name Symtuza. DRV/COBI/FTC/TAF constitutes a complete regimen for patients with...

  • Possible Safety Issue with Dolutegravir during Pregnancy: Reports of Neural Tube Defects

    Susa Coffey's picture

    On May 18, 2018, the U.S. Food and Drug Administration and the World Health Organization announced that cases of neural tube defects have been reported in babies of women with HIV who were on treatment with dolutegravir at the time of conception and during early pregnancy. The...

  • Darunavir/Cobicistat/FTC/TAF Single-Pill Combination in Treatment-Experienced Patients: EMERALD Study

    Susa Coffey's picture

    The EMERALD Study is a Phase III, open-label, noninferiority study in which 1,141 patients with stable HIV suppression on a regimen comprising a boosted protease inhibitor plus TDF/FTC were randomized (2:1) to either switch to an investigational single-tablet regimen containing...

  • Rifampin Drug-Drug Interactions with Newer Antiretrovirals (TAF, Bictegravir, Dolutegravir)

    Jennifer Cocohoba's picture

    Treatment of tuberculosis (TB) in HIV-infected persons remains challenging, in part because of drug interactions between rifampin and some ARVs that may compromise antiretroviral therapy (ART). Three studies presented at CROI provide clinicians with additional guidance on how to manage certain...

  • Naltrexone Improves Virologic Suppression

    Susa Coffey's picture

    Release from correctional settings is a high-stakes time for persons with HIV, as it is for those with other health issues. People with substance use disorders often relapse, and those with HIV often stop ART and do not engage in HIV care, increasing the risk of declines in...

  • Ibalizumab Approved for Persons with Multidrug Resistant HIV

    Susa Coffey's picture

    Ibalizumab (TNX-355), an entry inhibitor, has been approved by the FDA for use in persons with an extensive ARV treatment history and multidrug resistant HIV who are on a failing ARV regimen. Ibalizumab (trade name: Trogarzo) is a monoclonal antibody that binds the CD4 receptor and blocks HIV...

  • Bictegravir Approved for Initial ART, in Combination with TAF/FTC

    Susa Coffey's picture

    Bictegravir (BIC), a new integrase inhibitor, was recently approved by the FDA for use in a single-pill coformulation with TAF/FTC (brand name: Biktarvy) as initial therapy and as a switch regimen for patients who are already on a suppressive ART regimen and who have no history of...

  • Bictegravir/TAF/FTC in Women

    Susa Coffey's picture

    The single-pill combination of bictegravir (BIC) with tenofovir alafenamide (TAF) and emtricitabine (FTC), recently approved by the FDA, has been shown in four Phase III trials to be effective as initial therapy and as a switch regimen in patients with stably suppressed HIV RNA...

  • Immediate ART Initiation Improves Time to Viral Suppression

    Susa Coffey's picture

    The availability of ART immediately after the diagnosis of HIV offers many possible benefits, including earlier engagement in care and earlier HIV suppression, which may result in personal and public health benefits. Based on randomized clinical trials done in developing-world settings, the...

  • Undetectable = Untransmittable: Effective HIV Treatment Prevents HIV Transmission

    Susa Coffey's picture

    In September 2017, the U.S. Centers for Disease Control and Prevention (CDC) officially recognized that suppressing HIV through antiretroviral therapy (ART) prevents sexual transmission of HIV. In a "Dear Colleague" letter, CDC officials said, "people who take ART daily as prescribed and...

  • Doravirine in Initial Therapy: DRIVE-AHEAD Study

    Susa Coffey's picture

    Doravirine (DOR) is an investigational NNRTI that currently is being developed in a coformulation with TDF and FTC. A Phase 3 comparison of DOR + 2 NRTIs (87% of study subjects were given TDF/FTC) and DRV/r + 2 NRTIs in initial therapy was presented at CROI earlier this year (DRIVE-FORWARD); the...

  • Bictegravir in Initial Therapy

    Susa Coffey's picture

    Bictegravir (BIC) is an investigational integrase inhibitor that is being studied as part of a coformulation with tenofovir alafenamide (TAF) and emtricitabine (FTC). Two Phase 3 trials comparing a single-tablet regimen of BIC/TAF/FTC (50/25/200 mg) with regimens containing dolutegravir (DTG)...

  • On the Way: The First Protease Inhibitor-Based Single-Tablet Regimen

    Jennifer Cocohoba's picture

    The EMERALD Study is a Phase 3 randomized (2:1), open-label, noninferiority study examining the strategy of switching patients with suppressed HIV RNA on a regimen consisting of a boosted protease inhibitor plus tenofovir disoproxil fumarate (TDF)/emtricitabine to an investigational single-...

  • CROI 2017: Doravirine Noninferior to Darunavir + Ritonavir in Initial Treatment

    Susa Coffey's picture

    Doravirine is an investigational NNRTI that is active in vitro against many common NNRTI resistance mutations (including K103N, Y181C, and E138K). It is given once daily, has no food restrictions, and can be given with acid-blocking medications. In a Phase 2 study of treatment-...

  • CROI 2017: Bictegravir and Dolutegravir, Head-to-Head Comparison

    Susa Coffey's picture

     

    Bictegravir is an investigational integrase inhibitor that is dosed once daily, unboosted. It is active in vitro against many viruses with integrase resistance mutations. A Phase 2 double-blind placebo-controlled study randomized treatment-naive patients (n...

  • CROI 2017: Dolutegravir in 2-Drug Simplification Studies

    Susa Coffey's picture

    In recent years, a number of studies have evaluated 2-drug or even 1-drug ARV regimens, either in initial therapy or in switch regimens for patients with virologic suppression on 3-drug therapy. In general, these have not been as successful in achieving or maintaining virologic suppression as...

  • CROI 2017: Failure of Dolutegravir Monotherapy

    Susa Coffey's picture

    Leading up to this year, some researchers and clinicians had optimistically viewed dolutegravir an invincible ARV, a drug so mighty that it was unlikely to fail, and even more unlikely to be victim to emergent resistance mutations. Two presentations at CROI demonstrated the...

  • Journal Articles by AETC-Affiliated Researchers and Faculty--2016

    John Nelson's picture

    It's been a busy year for the AETC community, and we are proud to present the following compilation of published studies produced by members of our network during the 2016 calendar year.   Also included is the HRSA/HAB Workforce Survey results published in the AAHIVM HIV Specialist.  AETC-...

  • HIV Meds Update - RAPID: Immediate ART Initiation

    Susa Coffey's picture

    This publication presents the results of San Francisco General Hospital's Ward 86 pilot study of immediate ART initiation. This RAPID program systematically offered ART to patients upon diagnosis of HIV; patients were referred from HIV testing sites in San Francisco. Of the 39 patients who...

  • HIV Meds Update: Treatment as Prevention: Suppressive ART, Condomless Sex, and HIV Transmission Risk - also a Word on HPTN 052

    Susa Coffey's picture

    The PARTNER Study, a multisite European study, evaluated rates of HIV transmissions within serodifferent heterosexual and MSM couples (n = 548 and n = 340, respectively, contributed eligible data). The HIV-positive partners were on ART with HIV RNA levels of <200 copies/mL, and the couples...

  • HIV Meds Update: ART in Acute HIV--Decreasing HIV DNA

    Susa Coffey's picture

    We know that very early treatment in acute HIV infection decreases HIV RNA; this study shows it also greatly decreases proviral DNA (and reservoir size). Researchers investigated 2 small cohorts of patients in Thailand with acute (and very early) HIV infection, 1 untreated and 1 treated with ART...

  • HIV Meds Update: PrEP Uptake by Sex, Race, and Age

    Susa Coffey's picture

    At the ASM Microbe meeting in June, researchers from Gilead Sciences presented data on use of TDF/FTC (Truvada) PrEP in the United States according to sex and race. They evaluated national pharmacy databases to identify prescriptions of TDF/FTC given for PrEP between January 2012 and September...

  • Use of Dolutegravir in Dialysis

    Jennifer Cocohoba's picture

    Dolutegravir has several characteristics that, in theory, suggest it will not be significantly removed by dialysis: It has a large apparent volume of distribution (17.4 L) and is highly protein bound (98.9%). A small study of 5 HIV-infected patients with end-stage renal disease undergoing...

  • PrEP: Bone Density Improves after Stopping TDF/FTC

    Susa Coffey's picture

    Tenofovir disoproxil fumarate (TDF) may cause decreases in bone mineral density (BMD) both in HIV-infected patients treated with TDF-containing ARV regimens and in HIV-uninfected persons who use it for PrEP. A substudy of the large iPrEx trial of TDF/FTC PrEP in MSM and transgender...

  • Efavirenz, Dolutegravir, and Darunavir: Pharmacokinetics during Pregnancy

    Jennifer Cocohoba's picture

    Three studies presented at the 2016 Conference on Retroviruses and Opportunistic Infections (CROI) explored the pharmacokinetics of antiretrovirals administered during pregnancy. These studies support the use of standard-dose efavirenz, once-daily dolutegravir, and BID ritonavir-boosted...

  • Switching from TDF/FTC to TAF/FTC

    Susa Coffey's picture

    Researchers at the 2016 Conference on Retroviruses and Opportunistic Infections presented results from a randomized double-blind, double-dummy switch study of TAF/FTC. Over 660 patients with virologic suppression on TDF/FTC-containing 3-drug regimens were either switched to TAF/FTC (200/10 mg...

  • Tissue Levels of TAF: Too Low for PrEP?

    Susa Coffey's picture

    A pharmacokinetic study presented at the Conference on Retroviruses and Opportunistic Infections in Boston in February evaluated concentrations of tenofovir (TFV) and TFV-diphosphate (DP) in genital and rectal tissue and in anogenital fluid samples after administration of oral tenofovir...

  • Tips for Successful Linkage to Care

    Elizabeth I. Lazo's picture

    I would like to start this new year introducing myself to the AIDS Education and Training Center (AETC) community.  I had the pleasure of joining the AETC National Coordinating Resource Center (NCRC) as a Health Educator in December 2015.  I look forward to using my skill set as a Certified...

  • START-ing TEMPRANO: Early Initiation of Antiretroviral Therapy for HIV

    Jennifer Cocohoba's picture

    The prevailing opinion among experts regarding the optimal CD4 T-cell count at which to start patients on antiretroviral therapy (ART) has shifted several times during the evolution of HIV treatment. These shifts reflect attempts to strike a balance between preventing HIV-associated illness and...

  • Addressing the Gaps in the HIV Care Continuum for Women Living with HIV and their Partners: Recommendations for the National HIV/AIDS Strategy

    Mary Jo Hoyt's picture

    Annual meetings of the Centers for Disease Control and Prevention (CDC)-sponsored Elimination of Mother-to-Child Transmission of HIV (EMCT) Stakeholders Group and the Expert Panel on Reproductive Health and Preconception Care for Persons Living with HIV, held at the Washington...

Day Title
12/9 to 12/14